结合经典风险因素与乳腺密度的乳腺癌风险评估长期准确性
结果显示观察与预期浸润性乳腺癌病例数接近,含密度模型识别更多高风险女性,风险分层区分度良好且相对风险校准长期稳定。
要点
- Tyrer-Cuzick模型含密度预测的观察/预期比为0.98,不含密度为1.02,校准良好
- 含密度模型识别3.5%女性为高风险,高于不含密度模型的1.9%
- 最高风险十分位与中间80%相比的风险比为2.55(含密度)和2.22(不含密度)
核心结论
- 结合经典风险因素与乳腺密度的风险评估可提供10年以上的有效数据,或可指导长期风险适配的筛查与预防策略。
主要发现
- 中位随访5.2年期间诊断2699例浸润性乳腺癌,年发病率2.9/1000女性。
- Tyrer-Cuzick模型的观察/预期比为1.02(95%CI 0.98-1.06),含密度模型为0.98(95%CI 0.94-1.02)。
- Tyrer-Cuzick模型识别2554名(1.9%)高风险女性(10年风险≥8%),其中147例发生浸润性乳腺癌(O/E 0.79,95%CI 0.67-0.93;发病率8.7/1000)。
- 含密度模型识别4645名(3.5%)高风险女性,273例癌症(10.1%;O/E 0.78,95%CI 0.69-0.88;发病率9.2/1000)。
- 最高风险十分位与中间80%的风险比:Tyrer-Cuzick模型2.22(95%CI 2.02-2.45),含密度模型2.55(95%CI 2.33-2.80)。
临床怎么用
- 可将结合乳腺密度的Tyrer-Cuzick模型用于长期乳腺癌风险分层,辅助个体化筛查和预防干预决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Accurate long-term breast cancer risk assessment for women attending routine screening could help reduce the disease burden and intervention-associated harms by personalizing screening recommendations and preventive interventions. OBJECTIVE: To report the accuracy of risk assessment for breast cancer during a period of 19 years. DESIGN, SETTING, AND PARTICIPANTS: This cohort study of the Kaiser Permanente Washington breast imaging registry included women without previous breast cancer, aged 40 to 73 years, who attended screening from January 1, 1996, through December 31, 2013. Follow-up was completed on December 31, 2014, and data were analyzed from March 2, 2016, through November 13, 2017. EXPOSURES: Risk factors from a questionnaire and breast density from the Breast Imaging and Reporting Data System at entry; primary risk was assessed using the Tyrer-Cuzick model. MAIN OUTCOMES AND MEASURES: Incidence of invasive breast cancer was estimated with and without breast density. Follow-up began 6 months after the entry mammogram and extended to the earliest diagnosis of invasive breast cancer, censoring at 75 years of age, 2014, diagnosis of ductal carcinoma in situ, death, or health plan disenrollment. Observed divided by expected (O/E) numbers of cancer cases were compared using exact Poisson 95% CIs. Hazard ratios for the top decile of 10-year risk relative to the middle 80% of the study population were estimated. Constancy of relative risk calibration during follow-up was tested using a time-dependent proportional hazards effect. RESULTS: In this cohort study of 132 139 women (median age at entry, 50 years; interquartile range, 44-58 years), 2699 invasive breast cancers were subsequently diagnosed after a median 5.2 years of follow-up (interquartile range, 2.4-11.1 years; maximum follow-up, 19 years; annual incidence rate [IR] per 1000 women, 2.9). Observed number of cancer diagnoses was close to the expected number (O/E for the Tyrer-Cuzick model, 1.02 [95% CI, 0.98-1.06]; O/E for the Tyrer-Cuzick model with density, 0.98 [95% CI, 0.94-1.02]). The Tyrer-Cuzick model estimated 2554 women (1.9%) to be at high risk (10-year risk of ≥8%), of whom 147 subsequently developed invasive breast cancer (O/E, 0.79; 95% CI, 0.67-0.93; IR per 1000 women, 8.7). The Tyrer-Cuzick model with density estimated more women to be at high risk (4645 [3.5%]; 273 cancers [10.1%]; O/E, 0.78; 95% CI, 0.69-0.88; IR per 1000 women, 9.2). The hazard ratio for the highest risk decile compared with the middle 80% was 2.22 (95% CI, 2.02-2.45) for the Tyrer-Cuzick model and 2.55 (95% CI, 2.33-2.80) for the Tyrer-Cuzick model with density. Little evidence was found for a decrease in relative risk calibration throughout follow-up for the Tyrer-Cuzick model (age-adjusted slope, -0.003; 95% CI, -0.018 to 0.012) or the Tyrer-Cuzick model with density (age-adjusted slope, -0.008; 95% CI, -0.020 to 0.004). CONCLUSIONS AND RELEVANCE: Breast cancer risk assessment combining classic risk factors with mammographic density may provide useful data for 10 years or more and could be used to guide long-term, systematic, risk-adapted screening and prevention strategies.
引用
- Brentnall AR, Cuzick J, Buist DSM, et al. Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density. JAMA Oncol. 2018. PMID: 29621362. doi:10.1001/jamaoncol.2018.0174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。